MGC Pharmaceuticals Limited (MGCLF) Research

MGC Pharmaceuticals Limited is a biopharmaceutical company dedicated to the global development and provision of plant-derived medicines. The firm manufactures and distributes both medical cannabis products and a range of non-cannabis botanical therapeutics. Among its key investigational drug candidates are CimetrA, which is undergoing Phase III clinical trials for the symptomatic treatment of early-stage COVID-19; CannEpil, a Phase IIb cannabis-based therapy targeting drug-resistant epilepsy; and CogniCann, currently in Phase II clinical evaluation for the symptomatic relief of dementia. Beyond its core pipeline, MGC Pharmaceuticals also offers its ArtemiC product line, various cannabinoid-focused items, and other non-pharmaceutical goods. The company further extends its services to include consulting, particularly in clinical research. Established in 2014 and headquartered in West Perth, Australia, the company previously operated as Erin Resources Limited before rebranding to MGC Pharmaceuticals Limited in December 2015.

Market snapshot

Symbol
MGCLF
Price
$0.27
Day change
+2.88%
Market cap
$18.4M
P/E ratio
-0.06x
52-week range
0.225-5.1
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Antibe Therapeutics Inc. (ATBPF)
  • RIV Capital Inc. (CNPOF)
  • Eiger BioPharmaceuticals, Inc. (EIGRQ)
  • The Flowr Corporation (FLWPF)
  • Living Cell Technologies Limited (LVCLY)
  • Nuvo Pharmaceuticals Inc. (MRVFF)
  • Simply Better Brands Corp. (PKANF)
  • RAMM Pharma Corp. (RAMMF)

Open MGC Pharmaceuticals Limited (MGCLF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.